Seasonal variation of disease activity of systemic lupus erythematosus in Finland: a 1 year follow up study

Abstract Aim: TO assess the effects of rituximab (RTM) therapy on clinical and morphologic activity of lupus nephritis (LN). Material and methods: The study included 45 patients with confirmed diagnosis of systemic lupus erythematosus (SLE), unaffected by previously received standard therapy with glucocorticoids (GCs) and cytostatics. The disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K); to assess the LN activity we used the SLICC RA/RE index. Forty-five patients with LN were given puncture renal biopsy prior to prescribing RTM; 16 patients had repeated renal biopsy 1 year and more after beginning the anti-B-cell therapy. LN was graded histologically in accordance with the WHO classification (2003) with indices of activity (AI) and chronicity (CI). Results: The predominant number of patients had class III - IV of LN. The repeated renal biopsies demonstrated that LN had undergone a transition into a more favourable morphologic class, which was associated, in most of these cases, with a positive therapeutic effect. The follow-up dynamics showed a statistically significant reduction of AI (p=0.006), and no statistically significant changes in the CI (p = 0.14). Conclusion: The long-term follow-up in the study has showed that repeated courses of anti-B-cell therapy with RTM have a positive effect both on SLE activity and generally on the renal process. The reduction of the morphologic class of LN as assessed in the repeated renal biopsies is a convincing proof for this. Eleven out of 16 patients experienced transition of the morphologic class into a more favourable type, which in most cases was combined with lower AI (p = 0.006). We found no evidence of increase in the CI (p = 0.14).

Download Full-text

AB0486 Incidence of vertebral fractures: 8 years follow-up study in women with systemic lupus erythematosus

10.1136/annrheumdis-2017-eular.1238 ◽

2017 ◽

Author(s):

C Mendoza Pinto ◽

MDLL Leon Vazquez ◽

A Montiel Jarquin ◽

H Sandoval-Cruz ◽

MA Buendía Luca ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Vertebral Fractures ◽

Lupus Erythematosus ◽

Systemic Lupus ◽

Follow Up Study

Download Full-text

Dysfunction of CD27+IgD+B Cells Correlates With Aggravated Systemic Lupus Erythematosus

10.21203/rs.3.rs-800240/v1 ◽

2021 ◽

Author(s):

wei zhang ◽

YF Wang ◽

Fanlei Hu ◽

Fuai Lu ◽

Tao Wu ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

B Cells ◽

B Cell ◽

Lupus Erythematosus ◽

Statistical Significance ◽

Systemic Lupus ◽

Follow Up Study ◽

Healthy Control ◽

Natural Igm

Abstract Objective：The apoptotic signaling pathway is obviously disordered in systemic lupus erythematosus (SLE). Natural IgM (nIgM) is important in clearing apoptotic cells and preventing them from triggering deleterious autoimmunity. B-1- and innate-like B- (ILBs) cells are the main nIgM producers. Human CD27+IgD+B cells (un-switched memory B cells) are considered ILBs. However, their functional properties in SLE remain undefined.Methods：Peripheral blood samples of 50 SLE patients and 50 healthy control were collected, and twelve SLE patients were assessed in a follow-up study. The amounts of CD27+IgD+ B cell was analyzed by flow cytometry. The IgM and IL-10 levels of CD27+IgD+ B cell were assessed by ELISPOT and qRT-PCR. SPSS 17.0 (SPSS, USA) was employed for data analysis. P<0.05 indicated statistical significance.Result：92.0% were females, 17-67 years. CD27+IgD+B cell amounts are significantly decreased in SLE patients than healthy control (p<0.01). CD27+IgD+B cell amounts were positively correlated with WBC(r=0.337, p=0.017), platelet count(r=0.396, p=0.004) and serum C3 levels(r=0.415, p=0.003), CD27+IgD+B cell amounts showed negative correlations with serum creatinine levels(r=-0.285, p=0.045), SLEDAI(r=-0.724, p=0.000), anti-dsDNA(r=-0.477, p=0.000) and CRP(r=-0.398,p=0.004). The IgM and IL-10 levels of CD27+IgD+B in SLE were decreased than healthy control (p<0.001), moreover CD27+IgD+B cells are increased in SLE cases after treatment in SLE patients than before treatment(p<0.001).Conclusion：CD27+IgD+B cell amounts are significantly decreased and it was correlated with clinical and immunological features in SLE patients. CD27+IgD+B cells had impaired function regarding IgM and IL-10 production in SLE, however, CD27+IgD+B cells amounts are recovered in SLE cases with treatment-related disease remission.

Download Full-text

SAT0182 DYSLIPIDEMIA, HYPERTENSION, LUPUS NEPHRITIS AND HIGHER PREDNISONE USAGE CONTRIBUTE TO EVOLUTION OF CAROTID INTIMA-MEDIA THICKNESS IN MILD SYSTEMIC LUPUS ERYTHEMATOSUS: A 7-YEAR FOLLOW-UP STUDY

10.1136/annrheumdis-2019-eular.4863 ◽

2019 ◽

Author(s):

Sofia Ajeganova ◽

Thomas Gustafsson ◽

Tomas Jogestrand ◽

Ingiäld Hafström ◽

Johan Frostegård

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Nephritis ◽

Lupus Erythematosus ◽

Intima Media Thickness ◽

Carotid Intima Media Thickness ◽

Systemic Lupus ◽

Follow Up Study ◽

Media Thickness

Download Full-text

SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus

Lupus ◽

10.1177/0961203320965699 ◽

2020 ◽

Vol 29 (14) ◽

pp. 1914-1925

Author(s):

Sae Lim von Stuckrad ◽

Jens Klotsche ◽

Robert Biesen ◽

Mareike Lieber ◽

Julia Thumfart ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Disease Activity ◽

Lupus Erythematosus ◽

Clinical Course ◽

Youden Index ◽

Systemic Lupus ◽

Pediatric Systemic Lupus Erythematosus ◽

Elevated Expression ◽

Membrane Bound

Background To analyse the validity of membrane-bound SIGLEC1 (CD169) as a sensitive biomarker for monitoring disease activity in pediatric systemic lupus erythematosus (SLE). Methods 27 children and adolescents with SLE were followed for a mean of 13.5 months. During consecutive routine visits SLEDAI-2k, C3, C4 and ds-DNA values were determined. Additionally, expression of SIGLEC1 on monocytes was determined by flow cytometry. The amount of PE-labelled CD169 mAb bound per monocyte was analyzed using QuantiBRITE™ PE tubes. Associations between biomarkers and the clinical course were investigated by regression analysis. Results In general, SIGLEC1 expression is high on SLE-derived monocytes (mean 6 359 (SD 6 056) molecules/monocyte, cut-off 2 500 molecules/monocyte), all patients with newly diagnosed SLE exhibit elevated expression (mean 13366 (SD 7 750) molecules/monocyte). Changes (Δ) in SIGLEC1 levels during the clinical course is the only biomarker that significantly correlates with the change in SLEDAI-2k (betaST = 0.28, p = 0.001). At follow-up visit, a clinically important worsening was experienced by 47.6% of patients with a Δ SIGLEC1 > 2 151 molecules/cell (OR 5.31) and 72.4% with a Δ SIGLEC1 > 756 molecules/cell (OR 8.90). Conversely, 36.4% of patients with a Δ SIGLEC1 < -2 818 molecules/cell (OR 4.16, percentiles as cut-off criteria) and 50.0% of patients with a Δ SIGLEC1 < -1 370 molecules/cell (OR 3.55, application of Youden index) showed clinical improvement. SIGLEC1 expression correlates inversely with the amount of therapeutically applied hydroxychloroquine (p < 0.001). Conclusions SIGLEC1 expression on monocytes is a sensitive biomarker for adjusting disease activity in childhood SLE and represents a promising and easily applicable tool for disease monitoring.

Download Full-text